Nuvig Halts NVG-2089 CIDP Trial, Keeping Midstage ITP Study Running

Nuvig Therapeutics has halted development of NVG-2089 for chronic inflammatory demyelinating polyradiculoneuropathy, or CIDP, after concluding that the program could not advance quickly enough under the expected cost and enrollment timeline for that indication.

CEO David Woodhouse said the decision was not safety-related. The Palo Alto biotech is continuing a separate phase 2 study of the same fusion protein in immune thrombocytopenia, or ITP, and said it expects to share data from both the CIDP and ITP studies in the coming months, along with more information about the next indication it plans to pursue.

What Changed

According to Woodhouse, Nuvig stopped development in CIDP earlier this year because "the cost and expected enrollment timeline in CIDP would limit our ability to move the program forward as quickly as we would like." The phase 2 CIDP trial has stopped enrolling after taking in 14 patients since its April 2025 launch, according to the federal clinical trials database.

The company said the change does not come with layoffs or restructuring. That matters because NVG-2089 is Nuvig's sole clinical asset, while the rest of its pipeline remains preclinical.

Why It Matters

The decision is a reminder that for smaller biotechs, development risk is not only about efficacy or safety. Trial execution and financing can be just as determinative, especially in indications where recruitment is difficult and approved therapies already exist.

Several FDA-approved options are available for CIDP, including argenx's Vyvgart Hytrulo and Takeda's HyQvia, both of which were approved for the disease in 2024. In that setting, a company with one clinical-stage program may decide that capital and time are better spent on an indication with a clearer path to meaningful data.

Nuvig launched in 2022 with $47 million and backing from Novo Holdings and Bristol Myers Squibb. Sanofi and Bayer venture funds later joined its $161 million series B in December 2024. The immediate signal is that even well-backed private companies are tightening indication selection when trial speed and cost threaten to delay the broader program.